Clinical trial
Bortezomib, Lenalidomide and Dexamethasone Combination Therapy in Patients With…
NCT00378105 · Dana-Farber Cancer Institute, Other · Active, not recruiting
Key facts
| NCT number | NCT00378105 |
|---|---|
| Title | Bortezomib, Lenalidomide and Dexamethasone Combination Therapy in Patients With Newly Diagnosed Multiple Myeloma |
| Official title | An Open-Label Phase I/II Study of the Safety and Efficacy of Bortezomib, Lenalidomide and Dexamethasone Combination Therapy for Patients With Newly Diagnosed Multiple Myeloma |
| Lead sponsor | Dana-Farber Cancer Institute, Other |
| Collaborators | Brigham and Women's Hospital Beth Israel Deaconess Medical Center Massachusetts General Hospital Celgene Corporation Industry Millennium Pharmaceuticals, Inc. |
| Status | Active, not recruiting |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Multiple Myeloma |
| Intervention type | Drug |
| Interventions | Bortezomib, Lenalidomide, dexamethasone |
| Enrollment | 68 |
| Start date | Sep 1, 2006 |
| Primary completion | Jul 1, 2009 |
| Completion | Dec 1, 2025 |
| First posted | Sep 19, 2006 |
| Last update posted | Feb 28, 2025 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: